Fexofenadine hydrochloride in the treatment of allergic disease: a review

References

• AbdelazizMMDevaliaJLKhairOA1998Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitisJ Allergy Clin Immunol101410209525460
   PubMed Web of Science ®Google Scholar
• AdenotMLahanaRAdenotM2004Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substratesJ Chem Inf Comput Sci442394814741033
   PubMedGoogle Scholar
• AkiyamaSCornwellMMKuwanoM1988Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analogMol Pharmacol3314472893251
   PubMed Web of Science ®Google Scholar
• AlloccoFTVotypkaVdeTineoM2002Effects of fexofenadine on the early response to nasal allergen challengeAnn Allergy Asthma Immunol895788412487223
   PubMed Web of Science ®Google Scholar
• AsanoKKanaiKFurutaA2007Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivoJ Pharm Pharmacol5913899517910814
   PubMed Web of Science ®Google Scholar
• AsanoKKanaiKSuzakiH2004aSuppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitroArzneimittelforschung544364315460210
   PubMed Web of Science ®Google Scholar
• AsanoKKanaiKSuzakiH2004bSuppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitroInt Arch Allergy Immunol1332677514976396
   PubMed Web of Science ®Google Scholar
• AsanoKKanaiKISuzakiH2004cSuppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitroClin Exp Allergy341890815663564
   PubMed Web of Science ®Google Scholar
• BaltesSGastensAMFedrowitzM2007Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoproteinNeuropharmacology523334617045309
   PubMed Web of Science ®Google Scholar
• BanerjiALongAACamargoCAJr2007Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature reviewAllergy Asthma Proc284182617883909
   PubMed Web of Science ®Google Scholar
• BanfieldCGuptaSMarinoM2002Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadineClin Pharmacokinet41311811978146
   PubMed Web of Science ®Google Scholar
• BieloryLLeonovA2008Stereoconfiguration of antiallergic and immunologic drugsAnn Allerg Asthma Immunol10018
   PubMed Web of Science ®Google Scholar
• BowerEAMooreJLMossM2003The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnelAviat Space Environ Med741455212602446
   PubMed Web of Science ®Google Scholar
• BrannanJDAndersonSDGomesK2001Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitolAm J Respir Crit Care Med1631420511371412
   PubMed Web of Science ®Google Scholar
• BronskyEAFalliersCJKaiserHB1998Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergiesAllergy Asthma Proc19135419642436
   PubMed Web of Science ®Google Scholar
• CasaleTBAndradeCQuR1999Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitisAllergy Asthma Proc20193810389553
   PubMed Web of Science ®Google Scholar
• CassanoNFiloticoRD’ArgentoV2002In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticariaJ Eur Acad Dermatol Venereol16421212224713
   PubMed Web of Science ®Google Scholar
• CharukJHLooTWClarkeDM1994Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin AAm J Physiol266F66757905714
   PubMed Web of Science ®Google Scholar
• ChiouWLChungSMWuTC2000Potential role of P-glycoprotein in affecting hepatic metabolism of drugsPharm Res17903511028932
   PubMed Web of Science ®Google Scholar
• ChoiSUParkSHKimKH1998The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoproteinAnticancer Drugs9255619625436
   PubMed Web of Science ®Google Scholar
• CiprandiGCirilloIVizzaccaroA2004Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challengeAllerg Immunol (Paris)3614650
   Google Scholar
• Craig-McFeelyPMAcharyaNVShakirSA2001Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997Eur J Clin Pharmacol573132011549210
   PubMed Web of Science ®Google Scholar
• Craig-McFeelyPMFreemantleSLPearceGL2000QT lengthening and life-threatening arrhythmias associated with fexofenadineBr J Gen Pract5014810750216
   PubMed Web of Science ®Google Scholar
• CroweAIlettKFKarunajeewaHA2006aRole of P glycoprotein in absorption of novel antimalarial drugsAntimicrob Agents Chemother503504616917012
   PubMed Web of Science ®Google Scholar
• CroweATeohYKCroweA2006bLimited P-glycoprotein mediated efflux for anti-epileptic drugsJ Drug Target1429130016882549
   PubMed Web of Science ®Google Scholar
• CvetkovicMLeakeBFrommMF1999OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadineDrug Metab Dispos278667110421612
   PubMed Web of Science ®Google Scholar
• DharSHazraPKMalakarS2000Fexofenadine-induced QT prolongation: a myth or fact?Br J Dermatol1421260110848773
   PubMed Web of Science ®Google Scholar
• DicpinigaitisPVGayleYEDicpinigaitisPV2003Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary functionBr J Clin Pharmacol56501414651723
   PubMed Web of Science ®Google Scholar
• DiDiodatoGSharomFJ1997Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporterBiochem Pharmacol531789979256153
   PubMed Web of Science ®Google Scholar
• DoranAObachRSSmithBJ2005The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse modelDrug Metab Dispos331657415502009
   PubMed Web of Science ®Google Scholar
• DrescherSSchaeffelerEHitzlM2002MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadineBr J Clin Pharmacol535263411994059
   PubMed Web of Science ®Google Scholar
• DresserGKBaileyDGLeakeBF2002Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadineClin Pharmacol Ther71112011823753
   PubMed Web of Science ®Google Scholar
• DresserGKKimRBBaileyDG2005Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptidesClin Pharmacol Ther77170715735611
   PubMed Web of Science ®Google Scholar
• EjsingTBMorlingNLinnetK2007A review on the relation between the brain-serum concentration ratio of drugs and the influence of P-glycoproteinDrug Metabol Drug Interact221132917708063
   PubMedGoogle Scholar
• ElsingaPHHendrikseNHBartJ2004PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNSCurr Pharm Des10149350315134571
   PubMed Web of Science ®Google Scholar
• FaassenFVogelGSpaningsH2003Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugsInt J Pharm2631132212954186
   PubMed Web of Science ®Google Scholar
• FardonTCLeeDKHodgeMR2005Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthmaAnn Allergy Asthma Immunol952596516200817
   PubMed Web of Science ®Google Scholar
• FengBMillsJBDavidsonRE2008In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous systemDrug Metab Dispos362687517962372
   PubMed Web of Science ®Google Scholar
• FokkensWJBroekhuis-FluitsmaDMRijntjesE1991Langerhans cells in nasal mucosa of patients with grass pollen allergyImmunobiology182135421715843
   PubMed Web of Science ®Google Scholar
• FrommMF2000P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugsInt J Clin Pharmacol Ther38697410706193
   PubMed Web of Science ®Google Scholar
• GarriguesANugierJOrlowskiS2002A high-throughput screening microplate test for the interaction of drugs with P-glycoproteinAnal Biochem3051061412018951
   PubMed Web of Science ®Google Scholar
• GelfandEWCuiZHTakedaK2002Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsivenessJ Allergy Clin Immunol110859512110826
   PubMed Web of Science ®Google Scholar
• GiraudTGiraudT1999QT lengthening and arrhythmias associated with fexofenadine.[comment]Lancet3532072310376646
   PubMed Web of Science ®Google Scholar
• GouazeVLiuYYPrickettCS2005Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugsCancer Res653861715867385
   PubMed Web of Science ®Google Scholar
• GraftDFBernsteinDIGoldsobelA2001Safety of fexofenadine in children treated for seasonal allergic rhinitisAnn Allergy Asthma Immunol8722611476456
   PubMed Web of Science ®Google Scholar
• GrewalISFlavellRA1996A central role of CD40 ligand in the regulation of CD4+ T-cell responsesImmunol Today1741048854557
   PubMedGoogle Scholar
• GrubbeRENayakAKittnerB2007The pharmacokinetics (PK), safety and tolerability of fexofenadine HCL 6 mg/mL suspension in children with allergic rhinitis (AR): a multicenter, open-label, single-dose studyJ Allergy Clin Immunol119S143
   Web of Science ®Google Scholar
• HammanMABruceMAHaehner-DanielsBD2001The effect of rifampin administration on the disposition of fexofenadineClin Pharmacol Ther691142111240975
   PubMed Web of Science ®Google Scholar
• HampelFCKittnerBvan BavelJH2007Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitisAnn Allergy Asthma Immunol995495418219837
   PubMed Web of Science ®Google Scholar
• HandaSDograSKumarB2004Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. [see comment]J Dermatolog Treat1555714754652
   PubMedGoogle Scholar
• HankoETommarelloSWatchkoJF2003Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain.[see comment]Pediatr Res54441512904601
   PubMed Web of Science ®Google Scholar
• HayeshiRMasimirembwaCMukanganyamaS2006The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated effluxEur J Pharm Sci29708116846720
   PubMed Web of Science ®Google Scholar
• HindmarchIShamsiZKimberS2002An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteersClin Exp Allergy32133912002730
   PubMed Web of Science ®Google Scholar
• HindmarchIShamsiZStanleyN1999A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor functionBr J Clin Pharmacol48200610417497
   PubMed Web of Science ®Google Scholar
• HiranoH1989[Studies on the degranulation and histamine release of purified rat peritoneal mast cells. The inhibitory effect of histamine and other chemicals]Nippon Ika Daigaku Zasshi5639292478572
   PubMedGoogle Scholar
• IbrahimSPegginsJKnaptonA2000Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulationJ Pharmacol Exp Ther29512768311082465
   PubMed Web of Science ®Google Scholar
• IshizakaTIshizakaK1977Immunological events at the surface of basophil granulocytes and mast cells which induce degranulationScand J Respir Dis Suppl98132272408
   PubMedGoogle Scholar
• ItoTYanoITanakaK1997Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1J Pharmacol Exp Ther282955609262363
   PubMed Web of Science ®Google Scholar
• JetteLMurphyGFLeclercJM1995Interaction of drugs with P-glycoprotein in brain capillariesBiochem Pharmacol50170197503774
   PubMed Web of Science ®Google Scholar
• JohnsonWW2002P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistanceMethods Find Exp Clin Pharmacol245011412500430
   PubMedGoogle Scholar
• JuergensURDarlathWStoberM2006aDifferential effects of fexofenadine on arachidonic acid metabolism in cultured human monocytesPharmacology7640516254456
   PubMed Web of Science ®Google Scholar
• JuergensURGillissenAUenS2006bNew evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitroPharmacology781293517016062
   PubMed Web of Science ®Google Scholar
• KamathAVYaoMZhangY2005Effect of fruit juices on the oral bioavailability of fexofenadine in ratsJ Pharm Sci94233915570603
   PubMed Web of Science ®Google Scholar
• KameiHNodaYIshikawaK2003Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteersHum Psychopharmacol18611814696020
   PubMed Web of Science ®Google Scholar
• KawashimaMHaradaSTangoT2002Review of fexofenadine in the treatment of chronic idiopathic urticariaInt J Dermatol41701612390200
   PubMed Web of Science ®Google Scholar
• KawashimaMTangoTNoguchiT2003Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group studyBr J Dermatol14812122112828751
   PubMed Web of Science ®Google Scholar
• Ketabi-KiyanvashNWeissJHaefeliWE2003P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamineAddict Biol8413814690877
   PubMed Web of Science ®Google Scholar
• KharaschEDWalkerAHofferC2005Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combinationJ Clin Pharmacol45798815601808
   PubMed Web of Science ®Google Scholar
• KimRBKimRB2002Drugs as P-glycoprotein substrates, inhibitors, and inducersDrug Metab Rev34475411996011
   PubMed Web of Science ®Google Scholar
• KingMSuWChangAZuckermanA2001Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs.[see comment]Nat Neurosci42687411224543
   PubMed Web of Science ®Google Scholar
• KulthananKGritiyarangsanPSitakalinC2001Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticariaJ Med Assoc Thai84153911336071
   PubMedGoogle Scholar
• LeeCHLeeCH2002Differential regulation of P-glycoprotein genes in primary rat hepatocytes by collagen sandwich and drugsJ Cell Biochem86122012112011
   PubMed Web of Science ®Google Scholar
• LeungDY1998Molecular basis of allergic diseasesMol Genet Metab63157679608537
   PubMed Web of Science ®Google Scholar
• LeungSBendayanR1999Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugsCan J Physiol Pharmacol776253010543726
   PubMed Web of Science ®Google Scholar
• LingV1992Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugsCancer69260391348966
   PubMed Web of Science ®Google Scholar
• LitmanTSkovsgaardTSteinWD2003Pumping of drugs by P-glycoprotein: a two-step process?J Pharmacol Exp Ther3078465314534356
   PubMed Web of Science ®Google Scholar
• LooTWBartlettMCClarkeDM2003Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoproteinJ Biol Chem278397061012909621
   PubMed Web of Science ®Google Scholar
• MakowskiPPikulaS1997Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobioticsPol J Pharmacol49387949566041
   PubMedGoogle Scholar
• MansfieldLMendozaCFloresJ2003Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA). [erratum Ann Allergy Asthma Immunol, 2003; 91(2):167]Ann Allergy Asthma Immunol90554912775138
   PubMed Web of Science ®Google Scholar
• MeltzerEOScheinmannPRosado PintoJE2004Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis – a pooled analysis of three studiesPediatr Allergy Immunol152536015209959
   PubMed Web of Science ®Google Scholar
• MilgromHKittnerBLanierR2007Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years oldAnn Allergy Asthma Immunol993586317941284
   PubMed Web of Science ®Google Scholar
• MilneRWLarsenLAJorgensenKL2000Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothaleinPharm Res171511511303961
   PubMed Web of Science ®Google Scholar
• MiuraMUnoTTateishiT2007Pharmacokinetics of fexofenadine enantiomers in healthy subjectsChirality19223717230498
   PubMed Web of Science ®Google Scholar
• MiyabeSKoizukaIOchiK2003Effect of fexofenadine hydrochloride on cedar pollinosisAuris Nasus Larynx30SupplS61812543163
   PubMed Web of Science ®Google Scholar
• MollgardLHellbergESmolowiczA2001Interactions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patientsLeuk Lymphoma421778511699205
   PubMed Web of Science ®Google Scholar
• MorrisonDSahasranamanS2007The 30 mg dose of fexofenadine HCL 6 mg/mL suspension is bioequivalent to the marketed 30 mg tablet in healthy adult subjects under fasted conditions: a randomized crossover, open-label studyJ Allergy Clin Immunol119S143
   Web of Science ®Google Scholar
• NelsonHSReynoldsRMasonJ2000Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticariaAnn Allergy Asthma Immunol845172210831005
   PubMed Web of Science ®Google Scholar
• NeuhoffSLangguthPDresslerC2000Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolitesInt J Clin Pharmacol Ther381687910783826
   PubMed Web of Science ®Google Scholar
• NgamphaiboonJDirekwattanachaiCVisitsunthornN2005The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitisAsian Pac J Allergy Immunol231697416572735
   PubMed Web of Science ®Google Scholar
• NicholsonANStoneBMTurnerC2000Antihistamines and aircrew: usefulness of fexofenadineAviat Space Environ Med712610632124
   PubMed Web of Science ®Google Scholar
• OkuboKGotohMShimadaK2005Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis seasonInt Arch Allergy Immunol1361485415650312
   PubMed Web of Science ®Google Scholar
• OrlowskiSGarrigosM1999Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugsAnticancer Res1931092310652600
   PubMed Web of Science ®Google Scholar
• PascaudCGarrigosMOrlowskiS1998Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agentsBiochem J33335189657975
   PubMed Web of Science ®Google Scholar
• PetriNTannergrenCRungstadD2004Transport characteristics of fexofenadine in the Caco-2 cell modelPharm Res21139840415359574
   PubMed Web of Science ®Google Scholar
• PintoYMvan GelderICHeeringaM1999QT lengthening and life-threatening arrhythmias associated with fexofenadine. [see comment]Lancet35398010459910
   PubMed Web of Science ®Google Scholar
• PotterPCSchepersJMVan NiekerkCH2003The effects of fexofenadine on reaction time, decision-making, and driver behaviorAnn Allergy Asthma Immunol911778112952112
   PubMed Web of Science ®Google Scholar
• PrattCBrownAMRampeD1999Cardiovascular safety of fexofenadine HClClin Exp Allergy29Suppl 3212610444240
   PubMed Web of Science ®Google Scholar
• RebbeorJFSeniorAE1998Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted formBiochim Biophys Acta136985939528676
   PubMed Web of Science ®Google Scholar
• RidoutFHindmarchIRidoutF2003aThe effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteersAnn Allergy Asthma Immunol904041012722962
   PubMed Web of Science ®Google Scholar
• RidoutFShamsiZMeadowsR2003bA single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a carClin Ther2515183812867226
   PubMed Web of Science ®Google Scholar
• RobbinsDKCastlesMAPackDJ1998Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteersBiopharm Drug Dispos19455639818712
   PubMed Web of Science ®Google Scholar
• RussellTStoltzMWeirS1998Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteersClin Pharmacol Ther64612219871426
   PubMed Web of Science ®Google Scholar
• SafaARSafaAR2004Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulatorsCurr Med Chem Anti-Canc Agents4117
   PubMedGoogle Scholar
• SakairiTSuzukiKMakitaS2005Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitisPharmacology75768616037679
   PubMed Web of Science ®Google Scholar
• SaraswatASaraswatMSaraswatA2006Pustular exacerbation of psoriasis due to fexofenadineClin Exp Dermatol31477816681618
   PubMed Web of Science ®Google Scholar
• SavolainenJEdwardsJEMorganME2002Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in ratsDrug Metab Dispos304798211950774
   PubMed Web of Science ®Google Scholar
• SchinkelAHWagenaarEMolCA1996P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugsJ Clin Invest972517248647944
   PubMed Web of Science ®Google Scholar
• SharomFJ1997The P-glycoprotein efflux pump: how does it transport drugs?[see comment]J Membr Biol160161759425600
   PubMed Web of Science ®Google Scholar
• ShimizuMFuseKOkudairaK2005Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humansDrug Metab Dispos3314778116014768
   PubMed Web of Science ®Google Scholar
• ShirasakaYOnishiYSakuraiA2006Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugsBiol Pharm Bull2924657117142983
   PubMed Web of Science ®Google Scholar
• ShonJHYoonYRHongWS2005Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphismClin Pharmacol Ther7819120116084853
   PubMed Web of Science ®Google Scholar
• ShuklaSSaunaZEAmbudkarSV2008Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.[comment]Leukemia22445717690695
   PubMed Web of Science ®Google Scholar
• SimonsFEBergmanJNWatsonWT1996The clinical pharmacology of fexofenadine in childrenJ Allergy Clin Immunol98106248977506
   PubMed Web of Science ®Google Scholar
• SimonsFEstelleRSemusM2003H1-antihistaminic activity of cetirizine and fexofenadine in allergic childrenPediatr Allergy Immunol142071112787300
   PubMed Web of Science ®Google Scholar
• SmitJWDuinESteenH1998Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory levelBr J Pharmacol123361709504375
   PubMed Web of Science ®Google Scholar
• StoltzMArumughamTLippertC1997Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A)Biopharm Drug Dispos1864589330784
   PubMed Web of Science ®Google Scholar
• StoneBMTurnerCMillsSL1999Studies into the possible central effects of the H-1 receptor antagonist, fexofenadineInt Arch Allergy Immunol11833810224436
   PubMed Web of Science ®Google Scholar
• StorchCHTheileDLindenmaierH2007Comparison of the inhibitory activity of anti-HIV drugs on P-glycoproteinBiochem Pharmacol7315738117328866
   PubMed Web of Science ®Google Scholar
• TaharaHKusuharaHFuseE2005P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. [erratum Drug Metab Dispos, 200634(6):1079]Drug Metab Dispos33963815821041
   PubMed Web of Science ®Google Scholar
• TaharaHKusuharaHMaedaK2006Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecidDrug Metab Dispos34743716455804
   PubMed Web of Science ®Google Scholar
• TakahataTYasui-FurukoriNYoshiyaG2004Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substratesBasic Clin Pharmacol Toxicol94252615125696
   PubMed Web of Science ®Google Scholar
• TannergrenCKnutsonTKnutsonL2003The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion techniqueBr J Clin Pharmacol551829012580990
   PubMed Web of Science ®Google Scholar
• TashiroMHorikawaEMochizukiH2005Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone useHum Psychopharmacol20501916086364
   PubMed Web of Science ®Google Scholar
• TeraoTHisanagaESaiY1996Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrierJ Pharm Pharmacol48108398953513
   PubMed Web of Science ®Google Scholar
• TheunissenELJonkmanLMKuypersKP2006aA combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performanceJ Psychopharmacol2049650516174671
   PubMed Web of Science ®Google Scholar
• TheunissenELvan KroonenburghMJvan DeursenJA2006bStimulating effects of the antihistamine fexofenadine: testing the dopamine transporter hypothesisPsychopharmacology (Berl)1879510216767419
   PubMed Web of Science ®Google Scholar
• UnoTShimizuMSugawaraK2006Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadineDrug Metab Dispos341875916928786
   PubMed Web of Science ®Google Scholar
• van HeeswijkRPBourbeauMCampbellP2006Time-dependent interaction between lopinavir/ritonavir and fexofenadineJ Clin Pharmacol467586716809801
   PubMed Web of Science ®Google Scholar
• VercelliDJabaraHHAraiK1989Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigensJ Exp Med16912953072522501
   PubMed Web of Science ®Google Scholar
• WangJSZhuHJMarkowitzJS2006Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoproteinPsychopharmacology (Berl)1874152316810505
   PubMed Web of Science ®Google Scholar
• WangZHammanMAHuangSM2002Effect of St John’s wort on the pharmacokinetics of fexofenadine. [see comment]Clin Pharmacol Ther714142012087344
   PubMed Web of Science ®Google Scholar
• WatanabeNMatsudaEMasudaA2004The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralisInt Immunopharmacol43677515037214
   PubMed Web of Science ®Google Scholar
• WeilerJMBloomfieldJRWoodworthGG2000Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. [see comment]Ann Intern Med1323546310691585
   PubMed Web of Science ®Google Scholar
• WeissJKerpenCJLindenmaierH2003Interaction of antiepileptic drugs with human P-glycoprotein in vitroJ Pharmacol Exp Ther307262712954800
   PubMed Web of Science ®Google Scholar
• YiSYHongKSLimHS2004A variant 2677A allele of the MDR1 gene affects fexofenadine dispositionClin Pharmacol Ther764182715536457
   PubMed Web of Science ®Google Scholar